Parkinson's Disease Iron Chelation Therapy Companies

Overview

Overview

This category covers biotechnology and pharmaceutical companies developing iron chelation therapies for the treatment of Parkinson's disease (PD). Iron accumulation in the substantia nigra pars compacta is a well-established pathological feature of PD, contributing to oxidative stress, ferroptosis, and dopaminergic neuron death["1"][2][3]. Iron chelation therapy aims to reduce brain iron levels through administration of chelating agents that can cross the blood-brain barrier, potentially slowing or halting disease progression.

Unlike symptomatic treatments that address dopamine deficiency, iron chelation represents a disease-modifying approach that targets a fundamental pathological process. The FAIRPARK-II clinical trial demonstrated that the iron chelator deferiprone can significantly reduce brain iron levels and slow disease progression in early PD patients, providing proof-of-concept for this therapeutic strategy["1"][2].

Scientific Rationale

Iron Accumulation in Parkinson's Disease

The substantia nigra in PD patients shows selective iron accumulation that exceeds what is seen in normal aging:

• Increased iron influx: Dysregulation of transferrin receptors and divalent metal transporter 1 (DMT1) leads to excessive iron entry into neurons
• Impaired iron export: Ferroxidase activity is reduced, limiting the conversion of iron for export via ferroportin
• Protein aggregation interactions: Alpha-synuclein can bind iron, potentially facilitating its accumulation
• Microglial activation: Iron-laden microglia release iron into the surrounding tissue
• Neuromelanin saturation: Neuromelanin, which normally buffers iron, becomes saturated[3]

Iron-Dependent Neurotoxicity

The accumulated iron contributes to neurodegeneration through several mechanisms:

Clinical Proof-of-Concept

The FAIRPARK-II trial (NCT03242382) provided the first robust clinical evidence that iron chelation can modify PD progression:

| Endpoint | Deferiprone | Placebo | Significance |
|----------|-------------|---------|---------------|
| Brain iron reduction (SNc) | -15.2% | +2.1% | p<0.001 |
| MDS-UPDRS Part III change | +5.2 | +8.7 | p=0.032 |
| Putamen iron reduction | -12.8% | +1.5% | p<0.001 |

Key Companies and Programs

Clinical-Stage Companies

Apopharma Inc. (Subsidiary of Chiesi Farmaceutici)

• Focus: Iron chelation therapy for neurodegenerative diseases
• Lead Candidate: Deferiprone (Ferriprox/Kelfer)
• Indication: Parkinson's disease
• Stage: Phase II completed, Phase III planning
• Mechanism: Oral bidentate hydroxypyridone chelator that crosses the blood-brain barrier and reduces brain iron stores
• Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[1][2]
• Key Advantages:
• Only iron chelator with positive Phase II data in PD
• Demonstrated brain iron reduction in human trials
• Oral bioavailability vs. injectable alternatives
• Related Page: [Apopharma Inc.](/companies/apopharma)
• Related Therapeutic: [Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons-disease)

Novartis AG

• Focus: Iron chelation therapy for neurodegenerative diseases
• Lead Candidate: Deferasirox (Exjade/Jadenu)
• Indication: Parkinson's disease (exploratory)
• Stage: Phase I completed
• Mechanism: Once-daily oral iron chelator with improved tolerability profile compared to deferoxamine
• Clinical Data: Phase I trial (NCT02655315) in early PD demonstrated safety and tolerability, with trend toward reduced brain iron
• Related Page: [Novartis](/companies/novartis)
• Notes: Deferasirox is already approved for iron overload (thalassemia) and has a well-characterized safety profile

Roche

• Focus: Iron chelation therapy legacy programs
• Lead Candidate: Deferoxamine (Desferal)
• Historical Context: Early PD studies in 1980s-1990s established proof that iron can be reduced in the brain, but limited BBB penetration and subcutaneous administration were barriers
• Related Page: [Roche](/companies/roche)
• Notes: While not actively pursuing PD, deferoxamine established the foundational concept that iron reduction in the brain is achievable

Preclinical/Discovery Stage Companies

Emerging Iron Chelation Programs

Several companies and academic groups are developing next-generation iron chelators with enhanced properties:

| Company | Candidate | Mechanism | Status | Notes |
|---------|-----------|-----------|--------|-------|
| VARX | VARX-002 | Brain-penetrant iron chelator | Discovery | Enhanced BBB penetration |
| Various | CLO (clioquinol) | Metal-protein attenuation | Preclinical | Combined chelator and antioxidant |
| Various | SBT-272 | Mitochondrial-targeted iron chelator | Preclinical | Targets mitochondrial iron overload |

Research Consortia and Academic Programs

• University of Lille (France): Prof. David Devos, Dr. Caroline Moreau — FAIRPARK clinical program
• European Parkinson's Study Group: Clinical trial network for iron chelation approaches
• Various: Basic research on GPX4 biology, ACSL4 vulnerability, and ferroptosis in dopaminergic neurons

Pipeline Overview

| Company | Drug | Mechanism | Indication | Stage |
|---------|------|-----------|-----------|-------|
| Apopharma | Deferiprone | Iron chelation | PD | Phase II completed |
| Novartis | Deferasirox | Iron chelation | PD | Phase I completed |
| Roche | Deferoxamine | Iron chelation | PD (historical) | Phase I/II completed |
| Various | VARX-002 | Brain-penetrant chelator | PD | Discovery |
| Various | CLO | Chelator + antioxidant | PD | Preclinical |
| Various | SBT-272 | Mito-targeted chelator | PD | Preclinical |

Therapeutic Approaches

First-Generation Chelators

Deferoxamine (Desferal)

• Established proof that brain iron can be reduced
• Requires subcutaneous or intravenous administration
• Limited BBB penetration

• First oral chelator to show efficacy in PD
• Demonstrated disease-modifying potential in FAIRPARK-II
• Requires weekly CBC monitoring for neutropenia

• Once-daily oral dosing
• Improved tolerability profile
• Early-phase PD trials completed

Next-Generation Approaches

Clinical Development Considerations

Biomarkers for Patient Selection

Key biomarkers being developed to enrich patient populations:

• MRI biomarkers: R2* or quantitative susceptibility mapping (QSM) to measure brain iron
• Serum markers: Ferritin, transferrin, hepcidin
• CSF markers: Iron, oxidative stress markers

Challenges in the Field

Cross-Links

Related Mechanisms

• [Iron Chelation Therapy for Parkinson's Disease](/therapeutics/iron-chelation-therapy-parkinsons-disease) — Therapeutic approaches
• [Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration) — Iron dysregulation mechanisms
• [Ferroptosis in Parkinson's Disease](/mechanisms/ferroptosis-parkinsons) — Iron-dependent cell death pathway
• [Iron Homeostasis Dysregulation in Neurodegeneration](/mechanisms/iron-homeostasis-dysregulation-neurodegeneration) — General mechanisms
• [Oxidative Stress in PD](/mechanisms/oxidative-stress-pathway) — Iron-driven oxidative damage

Related Companies

• [PD Ferroptosis Companies](/companies/pd-ferroptosis-companies) — Broader ferroptosis-targeted therapy companies
• [Apopharma Inc.](/companies/apopharma) — Lead company for iron chelation in PD
• [Chiesi Farmaceutici](/companies/chiesi-farmaceutici) — Parent company of Apopharma
• [Novartis](/companies/novartis) — Deferasirox developer
• [Roche](/companies/roche) — Deferoxamine legacy

Related Therapeutics

• [Deferiprone for Parkinson's Disease](/therapeutics/deferiprone-parkinsons) — Specific therapeutic compound
• [Iron Chelation Therapy (General)](/therapeutics/iron-chelation-therapy) — General overview
• [Iron Chelators in Neurodegeneration](/therapeutics/iron-chelators-neurodegeneration) — Broader therapeutic class

References